Kim A Brogden

List of Publications by Year
in descending order

107 papers	8,263 citations	218381 26 h-index	102304 66 g-index
118 all docs	118 docs citations	118 times ranked	11811 citing authors

#	Article	IF	Citations
1	Dataset of endodontic microorganisms killed at 265 nm wavelength by an ultraviolet C light emitting diode in root canals of extracted, instrumented teeth. Data in Brief, 2022, 40, 107750.	0.5	6
2	Using ultraviolet (UV) light emitting diodes (LED) to create sterile root canals and to treat endodontic infections. Current Opinion in Biomedical Engineering, 2022, 23, 100397.	1.8	2
3	A distinguishing profile of chemokines, cytokines and biomarkers in the saliva of children with SjÃ¶grenâ€™s syndrome. Rheumatology, 2021, 60, 4765-4777.	0.9	12
4	Dataset-chemokines, cytokines, and biomarkers in the saliva of children with SjÃ¶gren's syndrome. Data in Brief, 2021, 36, 107139.	0.5	5
5	PD-L1 correlates with chemokines and cytokines in gingival crevicular fluid from healthy and diseased sites in subjects with periodontitis. BMC Research Notes, 2020, 13, 532.	0.6	7
6	Antimicrobial Prosthetic Surfaces in the Oral Cavityâ€”A Perspective on Creative Approaches. Microorganisms, 2020, 8, 1247.	1.6	13
7	Computational Models Accurately Predict Multi-Cell Biomarker Profiles in Inflammation and Cancer. Scientific Reports, 2019, 9, 10877.	1.6	9
8	HBD3 Induces PD-L1 Expression on Head and Neck Squamous Cell Carcinoma Cell Lines. Antibiotics, 2019, 8, 161.	1.5	4
9	255-nm Light-emitting Diode Kills Enterococcus faecalis and Induces the Production of Cellular Biomarkers in Human Embryonic Palatal Mesenchyme Cells and Gingival Fibroblasts. Journal of Endodontics, 2019, 45, 774-783.e6.	1.4	5
10	Dataset on the chemokine and cytokine responses of multi-cell cultures treated with Porphyromonas gingivalis hemagglutinin B. Data in Brief, 2019, 22, 964-970.	0.5	4
11	Human beta defensin 3 alters matrix metalloproteinase production in human dendritic cells exposed to Porphyromonas gingivalis hemagglutinin B. Journal of Periodontology, 2018, 89, 361-369.	1.7	5
12	Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy. BMC Cancer, 2018, 18, 225.	1.1	28
13	Promise of Combining Antifungal Agents in Denture Adhesives to Fight Candida Species Infections. Journal of Prosthodontics, 2018, 27, 755-762.	1.7	18
14	Matrix Metalloproteinase Response of Dendritic Cell, Gingival Epithelial Keratinocyte, and T-Cell Transwell Co-Cultures Treated with Porphyromonas gingivalis Hemagglutinin-B. International Journal of Molecular Sciences, 2018, 19, 3923.	1.8	14
15	Matrix metalloproteinase (MMP) and immunosuppressive biomarker profiles of seven head and neck squamous cell carcinoma (HNSCC) cell lines. Translational Cancer Research, 2018, 7, 533-542.	0.4	25
16	Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E3119-E3128.	3.3	147
17	Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCCâ€”a computational study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2017, 124, 157-164.	0.2	8
18	Diminished Antimicrobial Peptide and Antifungal Antibiotic Activities against Candida albicans in Denture Adhesive. Antibiotics, 2017, 6, 6.	1.5	8

#	Article	IF	Citations
19	PD-L1 is a diverse molecule regulating both tumor-intrinsic signaling and adaptive immunosuppression. Translational Cancer Research, 2016, 5, S1396-S1399.	0.4	8
20	Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models. Cancer Immunology, Immunotherapy, 2016, 65, 1511-1522.	2.0	17
21	Protein Analysis of Sapienic Acid-Treated Porphyromonas gingivalis Suggests Differential Regulation of Multiple Metabolic Pathways. Journal of Bacteriology, 2016, 198, 157-167.	1.0	6
22	MicroRNA-200c Represses IL-6, IL-8, and CCL-5 Expression and Enhances Osteogenic Differentiation. PLoS ONE, 2016, 11, e0160915.	1.1	53
23	Age-dependent variation in cytokines, chemokines and biologic analytes rinsed from the surface of healthy human skin. Scientific Reports, 2015, 5, 10472.	1.6	43
24	Differential cytotoxicity of long-chain bases for human oral gingival epithelial keratinocytes, oral fibroblasts, and dendritic cells. Data in Brief, 2015, 5, 285-291.	0.5	2
25	Differential cytotoxicity of long-chain bases for human oral gingival epithelial keratinocytes, oral fibroblasts, and dendritic cells. Toxicology Letters, 2015, 237, 21-29.	0.4	8
26	Cytotoxicity of HBD3 for dendritic cells, normal human epidermal keratinocytes, hTERT keratinocytes, and primary oral gingival epithelial keratinocytes in cell culture conditions. Toxicology Letters, 2015, 239, 90-96.	0.4	13
27	Antimicrobial Activity of Chemokine CXCL10 for Dermal and Oral Microorganisms. Antibiotics, 2014, 3, 527-539.	1.5	8
28	Human Î²-defensin HBD3 binds to immobilized Bla g2 from the German cockroach (Blattella germanica). Peptides, 2014, 53, 265-269.	1.2	3
29	The roles of cutaneous lipids in host defense. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 319-322.	1.2	64
30	Histatin 5 binds to Porphyromonas gingivalis hemagglutinin B (HagB) and alters HagB-induced chemokine responses. Scientific Reports, 2014, 4, 3904.	1.6	27
31	Oral inflammation, a role for antimicrobial peptide modulation of cytokine and chemokine responses. Expert Review of Anti-Infective Therapy, 2013, 11, 1097-1113.	2.0	18
32	Oral mucosal lipids are antibacterial against Porphyromonas gingivalis, induce ultrastructural damage, and alter bacterial lipid and protein compositions. International Journal of Oral Science, 2013, 5, 130-140.	3.6	46
33	Defensin DEFB103 bidirectionally regulates chemokine and cytokine responses to a pro-inflammatory stimulus. Scientific Reports, 2013, 3, 1232.	1.6	21
34	Antibacterial Activity of Sphingoid Bases and Fatty Acids against Gram-Positive and Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy, 2012, 56, 1157-1161.	1.4	182
35	The Emerging Role of Peptides and Lipids as Antimicrobial Epidermal Barriers and Modulators of Local Inflammation. Skin Pharmacology and Physiology, 2012, 25, 167-181.	1.1	61
36	Human Î²-defensin-3 alters, but does not inhibit, the binding of Porphyromonas gingivalis haemagglutinin B to the surface of human dendritic cells. International Journal of Antimicrobial Agents, 2012, 40, 75-79.	1.1	8

#	Article	IF	Citations
37	Perspectives and Peptides of the Next Generation. , 2011, , 423-439.		3
38	Will new generations of modified antimicrobial peptides improve their potential as pharmaceuticals?. International Journal of Antimicrobial Agents, 2011, 38, 217-25.	1.1	245
39	Influence of smoking on gingival crevicular fluid cytokines in severe chronic periodontitis. Journal of Clinical Periodontology, 2011, 38, 219-228.	2.3	152
40	Presence of wax esters and squalene in human saliva. Archives of Oral Biology, 2011, 56, 588-591.	0.8	28
41	Communication: Antimicrobial Activity of SMAP28 with a Targeting Domain for Porphyromonas gingivalis. Probiotics and Antimicrobial Proteins, 2010, 2, 21-25.	1.9	6
42	Defensins as anti-inflammatory compounds and mucosal adjuvants. Future Microbiology, 2010, 5, 99-113.	1.0	72
43	Defensins attenuate cytokine responses yet enhance antibody responses toPorphyromonas gingivalisadhesins in mice. Future Microbiology, 2010, 5, 115-125.	1.0	31
44	ChBac3.4: A Novel Proline-Rich Antimicrobial Peptide from Goat Leukocytes. International Journal of Peptide Research and Therapeutics, 2009, 15, 31-42.	0.9	26
45	Targeted antimicrobial activity of a specific IgGâ€“SMAP28 conjugate against Porphyromonas gingivalis in a mixed culture. International Journal of Antimicrobial Agents, 2009, 33, 14-20.	1.1	36
46	Human Î²â€defensin 3 binds to hemagglutinin B (rHagB), a nonâ€fimbrial adhesin from Porphyromonas gingivalis, and attenuates a proâ€inflammatory cytokine response. Immunology and Cell Biology, 2008, 86, 643-649.	1.0	74
47	Lentivirus Vector Can Be Readministered to Nasal Epithelia without Blocking Immune Responses. Journal of Virology, 2008, 82, 10684-10692.	1.5	86
48	Human Î±- and Î²-Defensins Bind to Immobilized Adhesins fromPorphyromonas gingivalis. Infection and Immunity, 2008, 76, 5714-5720.	1.0	22
49	Antimicrobial activity of cathelicidins BMAP28, SMAP28, SMAP29, and PMAP23 against Pasteurella multocida is more broad-spectrum than host species specific. Veterinary Microbiology, 2007, 119, 76-81.	0.8	32
50	Effects of polymicrobial communities on host immunity and response. FEMS Microbiology Letters, 2006, 265, 141-150.	0.7	14
51	Antimicrobial activity of Substance P and Neuropeptide Y against laboratory strains of bacteria and oral microorganisms. Journal of Neuroimmunology, 2006, 177, 215-218.	1.1	50
52	The nervous system and innate immunity: the neuropeptide connection. Nature Immunology, 2005, 6, 558-564.	7.0	388
53	Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?. Nature Reviews Microbiology, 2005, 3, 238-250.	13.6	4,822
54	Human polymicrobial infections. Lancet, The, 2005, 365, 253-5.	6.3	199

#	Article	IF	Citations
55	Surfactant protein D expression in normal and pneumonic ovine lung. Veterinary Immunology and Immunopathology, 2004, 101, 235-242.	0.5	17
56	Enhanced Surfactant Protein and Defensin mRNA Levels and Reduced Viral Replication during Parainfluenza Virus Type 3 Pneumonia in Neonatal Lambs. Vaccine Journal, 2004, 11, 599-607.	3.2	74
57	Antimicrobial peptides in animals and their role in host defences. International Journal of Antimicrobial Agents, 2003, 22, 465-478.	1.1	389
58	Increased Anionic Peptide Distribution and Intensity during Progression and Resolution of Bacterial Pneumonia. Vaccine Journal, 2002, 9, 28-32.	3.2	10
59	Mast cell density and substance P-like immunoreactivity during the initiation and progression of lung lesions in ovineMannheimia (Pasteurella) haemolytica pneumonia. Microbial Pathogenesis, 2001, 30, 325-335.	1.3	13
60	Response of the ruminant respiratory tract to Mannheimia (Pasteurella) haemolytica. Microbes and Infection, 2000, 2, 1079-1088.	1.0	119
61	Purification and Properties of Proline-Rich Antimicrobial Peptides from Sheep and Goat Leukocytes. Infection and Immunity, 1999, 67, 4106-4111.	1.0	101
62	Differences in the Concentrations of Small, Anionic, Antimicrobial Peptides in Bronchoalveolar Lavage Fluid and in Respiratory Epithelia of Patients with and without Cystic Fibrosis. Infection and Immunity, 1999, 67, 4256-4259.	1.0	39
63	Detection of Anionic Antimicrobial Peptides in Ovine Bronchoalveolar Lavage Fluid and Respiratory Epithelium. Infection and Immunity, 1998, 66, 5948-5954.	1.0	38
64	Cilia-associated Respiratory Bacillus in Wild Rats in Central Iowa. Journal of Wildlife Diseases, 1993, 29, 123-126.	0.3	21
65	Ultracentrifugation as a Means for the Separation and Identification of Lipopolysaccharides. ACS Symposium Series, 1990, , 238-249.	0.5	0
66	Response of Sheep after Localized Deposition of Lipopolysaccharide in the Lung. Experimental Lung Research, 1984, 7, 123-132.	0.5	28
67	Porcine Respiratory Disease Complex. , 0, , 231-258.		62
68	Cytopathology of Pathogenic Prokaryotes. , 0, , 424-523.		3
69	Taenia solium. , 0, , 229-243.		1
70	Parasitic Helminths. , 0, , 291-329.		4
71	Chlamydia pneumoniae and Chlamydia trachomatis. , 0, , 27-52.		6
72	Atrophic Rhinitis. , 0, , 169-197.		8

#	Article	IF	Citations
73	Cooperation between Viral and Bacterial Pathogens in Causing Human Respiratory Disease. , 0, , 199-212.		5
74	Respiratory Viruses and Bacteria in Cattle. , 0, , 213-229.		17
75	Mixed Infections of Intestinal Viruses and Bacteria in Humans. , 0, , 299-316.		3
76	Interactions between Herpesviruses and Bacteria in Human Periodontal Disease. , 0, , 317-331.		16
77	Interactions between Candida Species and Bacteria in Mixed Infections. , 0, , 357-373.		36
78	Virus-Induced Immunosuppression. , 0, , 375-387.		1
79	Concomitant Infections with Human Immunodeficiency Virus Type 1 and Human T-Lymphotropic Virus Types 1 and 2. , 0, , 75-97.		4
80	Viruses and Multiple Sclerosis. , 0, , 99-124.		4
81	Bacterial Vaginosis as a Mixed Infection. , 0, , 125-135.		6
82	Periodontal Diseases. , 0, , 137-152.		6
83	Sequelae of Chronic Viral Hepatitis. , 0, , 371-388.		0
84	Diseases with Long-Term Consequences in Search of a Microbial Agent. , 0, , 459-475.		0
85	Slow Viral Infections. , 0, , 389-406.		0
86	Infectious Causes of Chronic Disease: from Hypothesis to Proof. , 0, , 1-8.		0
87	Late Manifestations of Lyme Borreliosis. , 0, , 9-25.		0
88	Concluding Perspectives of Sequelae and Long-Term Consequences of Infectious Diseases-What's Next?. , 0, , 487-493.		0
89	Escherichia coli: Enteric and Extraintestinal Infections. , 0, , 69-85.		0
90	Complications of Superficial Mycoses. , 0, , 407-413.		0

#	Article	IF	Citations
91	Variable Capacity for Persistent Infection and Complications of Gram-Positive Cocci: Streptococci and Staphylococci. , 0, , 87-106.		0
92	Mycobacteria: Leprosy, a Battle Turned; Tuberculosis, a Battle Raging; Paratuberculosis, a Battle Ignored. , 0, , 135-167.		0
93	Whipple's Disease. , 0, , 205-216.		0
94	Epidemiological Methods To Implicate Specific Microorganisms with Long-Term Complications. , 0, , 477-486.		0
95	Mixed Mycotic Infections. , 0, , 333-356.		3
96	Infections with Multiple Hepatotropic Viruses. , 0, , 51-73.		3
97	Infection with Porphyromonas gingivalis, a Potential Risk Factor for Chronic Systemic Disease. , 0, , 443-457.		1
98	Abscesses. , 0, , 153-168.		0
99	Bovine Viral Diarrhea Virus in Mixed Infections. , 0, , 31-50.		3
100	Enteric Pathogens. , 0, , 53-68.		0
101	Acute Viral Infections with Rare Late Complications. , 0, , 331-337.		0
102	Latent Viral Infections. , 0, , 339-369.		0
103	Sequelae and Long-Term Consequences of Syphilis Infection. , 0, , 187-204.		1
104	Trypanosomatidae: Leishmania Species, Trypanosoma cruzi (Chagas Disease), and Associated Complications. , 0, , 275-289.		0
105	Toxoplasma gondii. , 0, , 217-228.		0
106	Sequelae and Long-Term Consequences of Systemic and Subcutaneous Mycoses. , 0, , 415-423.		0
107	Human Immunodeficiency Virus, Pneumocystis carinii, Toxoplasma gondii, and Leishmania Species. , 0, , 389-400.		0